Abstracts Archive - Page 1473 of 2425 - ACR Meeting Abstracts

Abstract Number: 829 • 2016 ACR/ARHP Annual Meeting
High Level of Chemokine CCL2 Is Associated with Lung Fibrosis Progression and Reduced Survival in Two Independent Systemic Sclerosis Cohorts
Anna Hoffmann-Vold¹, Richard Huyen², Elizabeth R. Volkmann², Oyvind Midtvedt¹, Vyacheslav Palchevskiy², May Brit Lund³, Torhild Garen¹, Trond Mogens Aalokken⁴, Anders Heiervang Tennøe¹, Stephen Samuel Weigt², Mike Shino², Rajan Saggar⁵, David Ross², Joseph Lynch III², Thor Ueland⁶, Michael Fishbein⁷, Pål Aukrust⁸, Øyvind Molberg¹ and John A Belperio², ¹Rheumatology, Oslo University Hospital, Oslo, Norway, ²University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ³Respiratory Medicine, Oslo University Hospital, Oslo, Norway, ⁴Radiology, Oslo University Hospital, Oslo, Norway, ⁵Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁶Research, Oslo University Hospital, Oslo, Norway, ⁷Pathology and Laboratory Medicine, University of California, Los Angeles, Los Angeles, CA, ⁸Research Intitute for Internal Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway
Background/Purpose: Markers for early identification of progressive interstitial lung disease (ILD) in systemic sclerosis (SSc) are in demand. The proto-typical inflammatory chemokine CCL2 has been linked…
Abstract Number: 830 • 2016 ACR/ARHP Annual Meeting
Cardiopulmonary Disease Development in Anti-RNA Polymerase III Positive Systemic Sclerosis; Comparative Analyses from an Unselected, Prospective Patient Cohort
Anna Hoffmann-Vold¹, Anders Heiervang Tennøe², Oyvind Midtvedt², May Brit Lund³, Torhild Garen², Fadi El-Hage⁴, Trond Mogens Aalokken⁵, Eli Taraldsrud⁴ and Øyvind Molberg², ¹Division of Rheumatology, Oslo University Hospital, Oslo, Norway, ²Rheumatology, Oslo University Hospital, Oslo, Norway, ³Respiratory Medicine, Oslo University Hospital, Oslo, Norway, ⁴Oslo University Hospital, Oslo, Norway, ⁵Radiology, Oslo University Hospital, Oslo, Norway
Background/Purpose: Extensive skin disease and renal crisis are hallmarks of anti-RNA polymerase III (RNAP) positive systemic sclerosis (SSc), while data on lung and heart involvement…
Abstract Number: 831 • 2016 ACR/ARHP Annual Meeting
Immunosuppression May Prevent Interstitial Lung Disease in Systemic Sclerosis
Sabrina Hoa¹, Marie Hudson², Mianbo Wang³, Russell Steele⁴, Murray Baron⁵ and Canadian Scleroderma Research Group, ¹Division of Rheumatology, Jewish General Hospital, Lady Davis Institute, Montreal, QC, Canada, ²Jewish General Hospital, Lady Davis Institute and McGill University, Montreal, QC, Canada, ³Lady Davis Institute for Medical Research, Montreal, QC, Canada, ⁴Mathematics, McGill University, Montreal, QC, Canada, ⁵Rheumatology, McGill University, Jewish General Hospital, Montreal, QC, Canada
Background/Purpose: Interstitial lung disease (ILD) is a leading cause of premature mortality in systemic sclerosis (SSc). Immunosuppression is used for treatment of established disease. However,…
Abstract Number: 832 • 2016 ACR/ARHP Annual Meeting
Defining Skin Ulcers in Systemic Sclerosis: A Systematic Literature Review of Skin Ulcer Definitions and a Preliminary Consensus-Based New SSc Skin Ulcer Definition
Yossra A Suliman¹, Cosimo Bruni², Sindhu R. Johnson³, Emanuela Praino⁴, Mohamed Alemam⁵, Nabeel Borazan⁶, Laura Cometi⁷, Bethany Myers⁸, Dinesh Khanna⁹, Yannick Allanore¹⁰, Murray Baron¹¹, Thomas Krieg¹², Ariane L. Herrick¹³, Suzanne Kafaja¹⁴, Christopher Denton¹⁵, Marco Matucci Cerinic¹⁶ and Daniel E. Furst¹⁷, ¹Rheumatology and Rehabilitation dept., Rheumatology and Rehabilitation dept. Assiut university hospital, Assiut Egypt, Assiut, Egypt, ²Department of Biomedicine, Division of Rheumatology AOUC, Excellence Centre for Research, Florence, Italy, ³Rheumatology, Mount Sinai Hospital and University Health Network, Toronto, ON, Canada, ⁴DIM, Rheumatology Unit, Bari, Italy, ⁵Clinical Pathology and Laboratory Medicine Department, Assistant Lecturer, Qena, Egypt, ⁶Medicine, David Geffen School of Medicine, Los Angeles, CA, ⁷Division of Rheumatology, Department of Experimental and Clinical Medicine,, Florencei, Italy, ⁸UCLA Louise M. Darling Biomedical Library, Research Informationist, Los Angeles, CA, ⁹University of Michigan, Ann Arbor, MI, ¹⁰Immunogenetics, Cochin Institute, Paris, France, ¹¹Rheumatology, McGill University, Jewish General Hospital, Montreal, QC, Canada, ¹²Universität zu Köln, Köln, Germany, ¹³Centre for Musculoskeletal Research, University of Manchester, MAHSC, Salford Royal Hospital, Manchester, United Kingdom, ¹⁴Medicine/Rheumatology, University of California Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ¹⁵Division of Medicine, Centre for Rheumatology and Connective Tissue Disease, University College London, London, United Kingdom, ¹⁶Department of BioMedicine, Division of Rheumatology, Transition Unit, University of Florence, Firenze, Italy, ¹⁷University of California, Los Angeles, Los Angeles, CA
Background/Purpose: Skin ulcers in SSc are a major clinical challenge and there are various un-validated definitions of skin ulcers utilized in SSc-related clinical trials. We…
Abstract Number: 833 • 2016 ACR/ARHP Annual Meeting
A Small Proportion of Patients with Systemic Sclerosis with Suspected Pulmonary Hypertension Meet the Published Inclusion/Exclusion Criteria for Two Systemic Sclerosis Associated Pulmonary Arterial Hypertension Screening Algorithms– Results from a Single Center Cohort
Amber Young¹, Victor Moles², Vivek Nagaraja³, Scott H. Visovatti⁴, Vallerie McLaughlin⁴ and Dinesh Khanna⁵, ¹Department of Internal Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, MI, ²Department of Internal Medicine, Division of Cardiology, University of Michigan, Ann Arbor, MI, ³Department of Medicine [Division of Rheumatology], University of Toledo, Toledo, OH, ⁴Internal Medicine, Division of Cardiology, University of Michigan, Ann Arbor, MI, ⁵University of Michigan, Ann Arbor, MI
Background/Purpose: Pulmonary arterial hypertension (PAH) is one of the leading causes of mortality in patients with systemic sclerosis (SSc). Active screening detects SSc-PAH earlier and…
Abstract Number: 834 • 2016 ACR/ARHP Annual Meeting
Distinctive Clinical Phenotype of Anti-Centromere Antibody Positive Diffuse Systemic Sclerosis
Joana Caetano¹, Svetlana Nihtyanova², Jennifer Harvey³, Christopher P.Denton⁴ and Voon H. Ong⁵, ¹Department of Medicine IV, Systemic Immunomediated Diseases Unit, Fernando Fonseca Hospital, Amadora, Portugal, ²Centre for Rheumatology and Connective Tissue Diseases, University College London Medical School, Royal Free Hospital, London, United Kingdom, ³Clinical Immunology, Royal Free Hospital, London, United Kingdom, ⁴Centre of Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom, ⁵Rheumatology, UCL Division of Medicine, London, United Kingdom
Background/Purpose: Although anti-centromere antibodies (ACA) typically associate with limited cutaneous subset of systemic sclerosis (lcSSc) this reactivity is also seen in some cases with diffuse…
Abstract Number: 835 • 2016 ACR/ARHP Annual Meeting
A Normal Pulmonary Diffusion Capacity Is Rare in Pulmonary Artery Hypertension in Systemic Sclerosis
Rebecca Overbury¹, Tracy M. Frech², Maureen Murtaugh³, Virginia D. Steen⁴ and PHAROS investigators, ¹Internal Medicine and Pediatrics, University of Utah, Salt Lake City, UT, ²Division of Rheumatology, University of Utah, Salt Lake City, UT, ³University of Utah, Salt Lake, UT, ⁴Rheumatology, Georgetown University Medical Center, Washington, DC
Background/Purpose: Methods: Results: > 70% (mean 78%) versus 191 patients (94.6%) who had a low DLCO <70% (mean 39%). There was no difference…
Abstract Number: 836 • 2016 ACR/ARHP Annual Meeting
Comprehensive Characterization of Calcinosis in a Multicenter International Cohort of Patients with Systemic Sclerosis
Antonia Valenzuela^1,2, Jessica K. Gordon³, Tatiana Sofia Rodriguez-Reyna⁴, Susanna Proudman^5,6, Murray Baron⁷, Monique Hinchcliff⁸, Dinesh Khanna⁹, Amber Young¹⁰, Flavia V. Castelino¹¹, Sara R. Schoenfeld¹², Virginia D. Steen¹³, David Fiorentino¹⁴ and Lorinda Chung¹⁵, ¹Division of Immunology and Rheumatology, Stanford University School of Medicine, Palo Alto, CA, ²Stanford University School of Medicine, Stanford, CA, ³Rheumatology, Hospital for Special Surgery, New York, NY, ⁴Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ⁵Rheumatology Unit, Royal Adelaide Hospital, Adelaide, Australia, ⁶Discipline of Medicine, University of Adelaide, Adelaide, Australia, ⁷Rheumatology, McGill University, Jewish General Hospital, Montreal, QC, Canada, ⁸Northwestern University, Feinberg School of Medicine Scleroderma Program, Chicago, IL, ⁹University of Michigan, Ann Arbor, MI, ¹⁰Department of Internal Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, MI, ¹¹Rheumatology, Allergy, Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ¹²Rheumatology Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ¹³Rheumatology, Georgetown University Medical Center, Washington, DC, ¹⁴Department of Dermatology, Stanford University School of Medicine, Palo Alto, CA, ¹⁵Rheumatology, Stanford University Medical Center, Palo Alto, CA
Background/Purpose: Calcinosis cutis is a debilitating complication of systemic sclerosis (SSc) affecting one quarter of patients. Repetitive trauma may be involved in the pathogenesis of…
Abstract Number: 837 • 2016 ACR/ARHP Annual Meeting
Development of a Skin-Specific Scleroderma Patient Reported Outcome Instrument
Ada Man¹, Jeannette K. Correa², Jessica Ziemek³, David T. Felson⁴ and Robert Lafyatis⁵, ¹Rheumatology, University of Manitoba, Winnipeg, MB, Canada, ²Psychology, Boston University, Boston, MA, ³Rheumatology, Boston University, Boston, MA, ⁴Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA, ⁵Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA
Background/Purpose: Skin fibrosis is the hallmark of SSc and may lead to significantly reduced quality of life in ways that may not be directly proportional…
Abstract Number: 838 • 2016 ACR/ARHP Annual Meeting
Esophageal Dysmotility and Interstitial Lung Disease in Patients with Scleroderma: A Retrospective Study
Shweta Kishore¹, Santhanam Lakshminarayanan¹, Chia-Ling Kuo² and Ranadeep Mandhadi¹, ¹Division of Rheumatology, University of Connecticut, Farmington, CT, ²Department of Community Medicine and Health Care, University of Connecticut, Farmington, CT
Background/Purpose: Systemic sclerosis (SSc) is a connective tissue disease with pulmonary involvement seen in 75% of patients and esophageal involvement in 90% of the patients.…
Abstract Number: 839 • 2016 ACR/ARHP Annual Meeting
Immunosuppression Does Not Prevent Severe Gastrointestinal Disease in Systemic Sclerosis
Nicolas Richard¹, Marie Hudson², Mianbo Wang³, Murray Baron⁴, Genevieve Gyger¹ and Canadian Scleroderma Research Group, ¹McGill University, Jewish General Hospital, Montreal, QC, Canada, ²Medicine/Rheumatology, Jewish General Hospital, Lady Davis Research Institute, Montreal, QC, Canada, ³Lady Davis Institute for Medical Research, Montreal, QC, Canada, ⁴Rheumatology, McGill University, Jewish General Hospital, Montreal, QC, Canada
Background/Purpose: Severe gastrointestinal (GI) disease is associated with considerable morbidity and high mortality in systemic sclerosis (SSc). There are no known preventative treatments. We wished…
Abstract Number: 840 • 2016 ACR/ARHP Annual Meeting
Time Trends in Incidence and Mortality of Systemic Sclerosis in Denmark from 1995-2011: A Nationwide Cohort Study
Sheraz Butt¹, Charlotte Andersson², Søren Jacobsen³, Gunnar Gislason⁴ and Christian Torp-Pedersen⁵, ¹Department of Medicine, Glostrup Hospital, Glostrup, Denmark, ²Department of Medicine, Glostrup Hospital, Copenhagen, Denmark, ³Center for Rheumatology and Spine Diseases, Rigshospitalet - Glostrup, University of Copenhagen, Denmark, Glostrup, Denmark, ⁴Department of Cardiology, Gentofte Hospital, Copenhagen, Denmark, ⁵Aalborg University, Aalborg, Denmark
Time Trends In Incidence And Mortality Of Systemic Sclerosis In Denmark From 1995-2011: A Nationwide Cohort Study Background/Purpose: Epidemiological studies have documented an increasing incidence…
Abstract Number: 841 • 2016 ACR/ARHP Annual Meeting
Low Nucleoside Triphosphate Pyrophosphohydrolase Activity Contributes to Pathologic Mineralization in Systemic Sclerosis
Yue Ding¹, Supraja Yeturi¹, Claudia Gohr¹, Mary Ellen Csuka¹ and Ann K. Rosenthal^2,3, ¹Medicine, Medical College of Wisconsin, Milwaukee, WI, ²Division of Rheumatology, Medical College of Wisconsin, Milwaukee, WI, ³Medicine, Clement J. Zablocki VA Medical Center, Milwaukee, WI
Background/Purpose: Calcinosis is a major source of morbidity in patients with systemic sclerosis (SS). In addition, increased coronary calcification has been reported in patients with…
Abstract Number: 842 • 2016 ACR/ARHP Annual Meeting
Aminaphtone Treatment Increases Skin Blood Perfusion and Related Clinical Symptoms in Patients Affected By Raynaud’s Phenomenon: A Pilot Study Based on Laser Speckle Contrast Analysis
Barbara Ruaro, Sabrina Paolino, Carmen Pizzorni, Maurizio Cutolo and Alberto Sulli, Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, Genova, Italy
Background/Purpose: Aminaphtone is an oral vasoactive drug used to treat microvascular impairement since 30 years, and recently suggested to down-regulate endothelin-1 production by endothelial cells,…
Abstract Number: 843 • 2016 ACR/ARHP Annual Meeting
Forced Vital Capacity Predicts Outcome in Scleroderma Associated Interstitial Lung Disease with Concomitant Pulmonary Hypertension: Data from the Pharos Registry
Joyce Sujin Lee¹, Jessica K. Gordon², Jackie Szymonifka³, Virginia Steen⁴ and Aryeh Fischer⁵, ¹SOM-MED, University of Colorado, Denver - Anschutz Medical Campus, Aurora, CO, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³Epidemiology and Biostatistics, Hospital for Special Surgery, New York, NY, ⁴Georgetown University School of Medicine, Washington, DC, ⁵Medicine / Center for Lungs and Breathing, University of Colorado School of Medicine, Aurora, CO
Forced vital capacity predicts outcome in scleroderma associated interstitial lung disease with concomitant pulmonary hypertension: Data from the PHAROS registry Background/Purpose: Interstitial lung disease…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].